148 related articles for article (PubMed ID: 17156592)
1. 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.
Higa GM; Auber ML; Altaha R; Piktel D; Kurian S; Hobbs G; Landreth K
J Oncol Pharm Pract; 2006 Dec; 12(4):201-9. PubMed ID: 17156592
[TBL] [Abstract][Full Text] [Related]
2. Concordance between substance P levels and antiemetic guidelines.
Higa GM; Auber ML; Altaha R; Kurian S; Hobbs G
J Support Oncol; 2009; 7(4):138-42. PubMed ID: 19731580
[TBL] [Abstract][Full Text] [Related]
3. Re: 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.
Hartvig P
J Oncol Pharm Pract; 2007 Mar; 13(1):57-8. PubMed ID: 17621570
[No Abstract] [Full Text] [Related]
4. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community.
Hickok JT; Roscoe JA; Morrow GR; King DK; Atkins JN; Fitch TR
Cancer; 2003 Jun; 97(11):2880-6. PubMed ID: 12767103
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
[TBL] [Abstract][Full Text] [Related]
6. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.
Grunberg SM; Deuson RR; Mavros P; Geling O; Hansen M; Cruciani G; Daniele B; De Pouvourville G; Rubenstein EB; Daugaard G
Cancer; 2004 May; 100(10):2261-8. PubMed ID: 15139073
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of droperidol in the prevention of cisplatin-induced delayed emesis: a double-blind, randomised parallel study.
Minegishi Y; Ohmatsu H; Miyamoto T; Niho S; Goto K; Kubota K; Kakinuma R; Kudoh S; Nishiwaki Y
Eur J Cancer; 2004 May; 40(8):1188-92. PubMed ID: 15110882
[TBL] [Abstract][Full Text] [Related]
8. Use of intravenous microdialysis to monitor changes in serotonin release and metabolism induced by cisplatin in cancer patients: comparative effects of granisetron and ondansetron.
Castejon AM; Paez X; Hernandez L; Cubeddu LX
J Pharmacol Exp Ther; 1999 Dec; 291(3):960-6. PubMed ID: 10565811
[TBL] [Abstract][Full Text] [Related]
9. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
[TBL] [Abstract][Full Text] [Related]
10. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
[TBL] [Abstract][Full Text] [Related]
11. Acute and delayed nausea and emesis control in pediatric oncology patients.
Holdsworth MT; Raisch DW; Frost J
Cancer; 2006 Feb; 106(4):931-40. PubMed ID: 16404740
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel marker associated with risk for delayed chemotherapy-induced vomiting.
Higa GM; Auber ML; Hobbs G
Support Care Cancer; 2012 Nov; 20(11):2803-9. PubMed ID: 22350597
[TBL] [Abstract][Full Text] [Related]
13. Urinary 5-hydroxyindoleacetic acid (5-HIAA) excretion during multiple-day high-dose chemotherapy.
Janes RJ; Muhonen T; Karjalainen UP; Wiklund T
Eur J Cancer; 1998 Jan; 34(1):196-8. PubMed ID: 9624258
[TBL] [Abstract][Full Text] [Related]
14. Intravenous ondansetron plus intravenous dexamethasone with different ondansetron dosing schedules during multiple cycles of cisplatin-based chemotherapy.
Chen PT; Liaw CC
Chang Gung Med J; 2008; 31(2):167-74. PubMed ID: 18567417
[TBL] [Abstract][Full Text] [Related]
15. Aprepitant (EMEND): the role of substance P in nausea and vomiting.
Prommer E
J Pain Palliat Care Pharmacother; 2005; 19(3):31-9. PubMed ID: 16219609
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetic investigation of 5-day multiple dose of tropisetron capsule in patients who had received cisplatin and the usefulness of tropisetron capsule in the treatment of nausea and vomiting].
Suminaga M; Akasaka Y; Nukariya N; Kimura A; Ohtawa M
Gan To Kagaku Ryoho; 1995 Aug; 22(9):1209-21. PubMed ID: 7544965
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced nausea and vomiting in the treatment of gastrointestinal tumors and secondary prophylaxis with aprepitant.
Abbrederis K; Lorenzen S; Rothling N; Ihbe-Heffinger A; Schuster T; Peschel C; Lordick F
Onkologie; 2009 Feb; 32(1-2):30-4. PubMed ID: 19209016
[TBL] [Abstract][Full Text] [Related]
18. [Relationship between cancer chemotherapeutic drug-induced delayed emesis and plasma levels of substance P in two patients with small cell lung cancer].
Matsumoto S; Kawasaki Y; Mikami M; Nakamoto M; Tokuyasu H; Kometani Y; Chikumi H; Hitsuda Y; Matsumoto Y; Sasaki T
Gan To Kagaku Ryoho; 1999 Mar; 26(4):535-8. PubMed ID: 10097753
[TBL] [Abstract][Full Text] [Related]
19. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G
Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369
[TBL] [Abstract][Full Text] [Related]
20. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
